Samedan Ltd Pharmaceutical Publishers


Advanced search

Publications European Pharmaceutical Contractor European Biopharmaceutical Review International Clinical Trials Pharmaceutical Manufacturing and Packing Sourcer Innovations in Pharmaceutical Technology Subscribe Online Conferences White Papers Samedan app Pharmaceutical Directory Industry Events Calendar News and Press Releases Employment Opportunities Advertising with us Contact Us

home > ebr > winter 2022 > modelling genetic disease: ips cell line development using gene editing

PUBLICATIONS

Dear guest!
To access full content of this article, please take a minute to become a member of this site. As a registered user you will be able to view all of our vast archive's material at any time. Sign up now!

Already registered? Please sign in.

Alternatively, please use our pay-per-view service.

News and Press Releases

Abzena bolsters senior leadership team with two key appointments

San Diego, CA, 14th March 2023 – Abzena, the leading end-to-end integrated CDMO for Antibody Drug Conjugates (ADCs) and complex biologic molecules, has strengthened its senior leadership team with the appointment of Joe Principe as Chief Commercial Officer, and Matthew Pinkston as Vice President, Program Management.
More info >>

All releases >>